Methods and products for expressing proteins in cells

Patent metadata

Field	Value
Publication number	US-9487768-B2
Application number	US-201615156829-A
Country	US
Kind code	B2
Filing date	May 17, 2016
Priority date	Nov 1, 2012
Publication date	Nov 8, 2016
Grant date	Nov 8, 2016

Abstract

The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.

First claim

What is claimed is:

1. A composition comprising a nucleic acid encoding a gene-editing protein, the gene-editing protein comprising: (a) a DNA-binding domain, and (b) a nuclease domain wherein:
(a) the DNA-binding domain comprises a plurality of repeat sequences and
at least one of the repeat sequences comprises the amino acid sequence: LTPvQVVAIAwxyzGHGG (SEQ ID NO: 75) and is between 36 and 39 amino acids long, wherein:
“v” is E,
“w” is S,
“x” is N,
“y” is S or D, and
“z” is GGKQALETVQRLLPVLCQA (SEQ ID NO: 671); and

(b) the nuclease domain comprises the catalytic domain of a nuclease.

2. The composition of claim 1 , wherein the nuclease domain is capable of forming a dimer with another nuclease domain.

3. The composition of claim 1 , wherein the gene-editing protein is capable of generating a nick or double-strand break in the target DNA molecule.

4. The composition of claim 1 , wherein the nucleic acid is a synthetic RNA molecule.

5. The composition of claim 4 , wherein the synthetic RNA molecule comprises one or more non-canonical nucleotides.

6. The composition of claim 5 , wherein the non-canonical nucleotide is 5-methylcytidine.

7. The composition of claim 1 , wherein the nuclease domain comprises the catalytic domain of a protein comprising the amino acid sequence of SEQ ID NO: 53.

8. The composition of claim 1 , wherein the nuclease is FokI.

9. The composition of claim 1 , wherein at least one of the repeat sequences contains a region capable of binding to a binding site in a target DNA molecule, the binding site containing a defined sequence of between 1 and 5 bases in length.

Assignees

• Factor Bioscience Inc

Inventors

• Angel Matthew
• Rohde Christopher

Classifications

• A61P5/00

  Drugs for disorders of the endocrine system · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P5/14

  of the thyroid hormones, e.g. T3, T4 · CPC title

• A61P25/16

  Anti-Parkinson drugs · CPC title